Tango Therapeutics, Inc.
TNGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819133
In the last 90 days, Tango Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $6.60B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $3.83B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.73M in total
- 5
- 13F holdersQ2 2026, +55 vs. previous quarter
- 247
- 13F valueReported value at the end of Q2 2026
- $6.60B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $62.4M
- +48.3% year over year
- Net income, FY2025
- -$101.6M
- No comparable prior period
- Free cash flow, FY2025
- -$139.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $101.6M (162.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 44.8M
- Shares sold short
- Change
- +277.5K
- +0.6% vs. previous
- Days to cover
- 11.16
- At average daily volume
Superinvestors holding TNGX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TNGX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Tango Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)7:35 PM ET | Nov 2 | 2 days | Crystal AdamPresident, R&D | SSale | −5.00K | $22.42 | −$112.1K | −4.1%115.7K after | 2 lots10b5-1 |
| Nov 4, 2026 (view filing)7:32 PM ET | Nov 2 | 2 days | Newcomb JessicaPrincipal Accounting Officer | SSale | −7.03K | $22.42 | −$157.7K | −11.9%52.1K after | 2 lots10b5-1 |
| Oct 5, 2026 (view filing)5:36 PM ET | Oct 1 | 4 days | Crystal AdamPresident, R&D | SSale | −27.0K | $24.47 | −$660.8K | −18.9%115.7K after | 2 lots10b5-1 |
| Sep 24, 2026 (view filing)7:41 PM ET | Sep 22 | 2 days | Newcomb JessicaPrincipal Accounting Officer | SSale | −8.20K | $24.22 | −$198.6K | −12.2%59.1K after | 3 lots10b5-1 |
| Sep 3, 2026 (view filing)4:01 PM ET | Sep 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.37 | −$603.9K | −18.9%115.7K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 3 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $27.24 | −$735.5K | −18.9%115.7K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)7:23 PM ET | Jul 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $29.59 | −$798.9K | −18.9%115.7K after | 2 lots10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.88 | −$617.6K | −18.9%115.7K after | 2 lots10b5-1 |
| May 5, 2026 (view filing) | May 1 | 4 days | Crystal AdamPresident, R&D | SSale | −27.0K | $21.22 | −$573.0K | −18.9%115.7K after | 2 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 15 | 1 day | Crystal AdamPresident, R&D | SSale | −38.5K | $25.00 | −$961.5K | −25.5%112.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 247 holdersThe largest institutional positions in Tango Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 13,900,620 | $434.5M | 3.71% | +600,000+4.5% | Added |
| BlackRock, Inc. | 12,438,444 | $388.8M | 0.01% | +3,690,399+42.2% | Added |
| FMR LLC | 12,333,339 | $385.5M | 0.02% | +2,427,420+24.5% | Added |
| Farallon Capital Management, L.L.C. | 12,277,000 | $383.8M | 2.25% | +3,179,589+35.0% | Added |
| Boxer Capital Management, LLC | 10,876,219 | $340.0M | 25.61% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 9,980,620 | $312.0M | 0.03% | +4,904,228+96.6% | Added |
| TCG Crossover Management, LLC | 9,081,201 | $283.9M | 6.82% | −1,449,870−13.8% | Reduced |
| Paradigm Biocapital Advisors LP | 6,357,523 | $198.7M | 3.72% | +2,347,844+58.6% | Added |
| Price T Rowe Associates Inc | 6,348,827 | $198.5M | 0.02% | +5,459,427+613.8% | Added |
| Siren, L.L.C. | 6,179,364 | $193.2M | 3.92% | +522,259+9.2% | Added |
Holders of 5% or more of TNGX
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Tango Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%25.3M shares | +8.10 ppfrom 6.90% | Feb 9, 20227 filings | Nov 6, 2026 | SEC |
| BCTG Holdings, LLC | 13D/A | 10.00%10.7M shares | – | Feb 16, 20216 filings | Jan 2, 2025 | SEC |
| Farallon Partners L L C | 13G/A | 9.99%13.5M shares | – | Feb 6, 20261 filing | Feb 6, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 9.80%16.3M shares | – | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| RTW Investments, LP | 13G | 9.30%13.3M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |